Trial Scorecard: Celebrate Successes
- Here's a summary of the key findings from the CELEBRATE trial, as reported by Healio:
- the CELEBRATE trial involved 2,467 patients experiencing symptoms suggestive of STEMI (heart attack) for less than 4 hours. Participants were randomly assigned to receive either a single subcutaneous...
- * Improved Efficacy: Patients receiving zalunfiban had a lower risk of a composite primary efficacy endpoint, encompassing all-cause death, stroke, recurrent MI, acute stent thrombosis, new-onset heart failure/HF...
CELEBRATE Trial Shows Positive Results for Zalunfiban in STEMI Patients
Here’s a summary of the key findings from the CELEBRATE trial, as reported by Healio:
What was studied?
the CELEBRATE trial involved 2,467 patients experiencing symptoms suggestive of STEMI (heart attack) for less than 4 hours. Participants were randomly assigned to receive either a single subcutaneous injection of zalunfiban (RUC-4, CeleCor Therapeutics) or a placebo at the first point of medical contact (home, ambulance, or hospital).
Key Findings:
* Improved Efficacy: Patients receiving zalunfiban had a lower risk of a composite primary efficacy endpoint, encompassing all-cause death, stroke, recurrent MI, acute stent thrombosis, new-onset heart failure/HF rehospitalization, larger infarct size, or no endpoint at 30 days.They also showed higher rates of adverse event-free survival.
* Improved Safety: The risk of severe or life-threatening bleeding was lower in the zalunfiban group.
* faster Blood Flow: Angiography results indicated faster coronary blood flow in patients treated with zalunfiban.
Where to find more information:
* The results were presented at the American Heart Association scientific Sessions.
* The study was together published in NEJM Records.
* You can find complete coverage of AHA 2025 on Healio: https://www.healio.com/news/cardiology/meeting-news/american-heart-association
Healio AI: Healio also promotes its AI tool, allowing users to ask clinical questions and access a knowledge base including PubMed, trials, guidelines, and Healio’s news coverage.